Clover Biopharmaceuticals (HKSE:02197) ROCE % : -583.54% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Clover Biopharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was -583.54%.

Clover Biopharmaceuticals ROCE % Historical Data

The historical data trend for Clover Biopharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals ROCE % Chart

Clover Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-24.10

-143.53

-280.85

-91.07

-13.86

Clover Biopharmaceuticals Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-294.34	-76.31	-114.14	101.27	-583.54

Clover Biopharmaceuticals ROCE % Calculation

Clover Biopharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-131.052	/	( ( (5242.647 - 3159.415)	+	(2298.504 - 2490.538) )	/ 2 )
	=	-131.052	/	( (2083.232	+	-192.034)	/ 2 )
	=	-131.052	/	945.599
	=	-13.86 %

Clover Biopharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-1711.084	/	( ( (3367.8 - 2589.321)	+	(2298.504 - 2490.538) )	/ 2 )
	=	-1711.084	/	( ( 778.479	+	-192.034 )	/ 2 )
	=	-1711.084	/	293.2225
	=	-583.54 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Clover Biopharmaceuticals (HKSE:02197) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Clover Biopharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clover Biopharmaceuticals (HKSE:02197) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN

Website

https://www.cloverbiopharma.com

Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.

Executives

Liang Peng	2101 Beneficial owner
Liang Joshua G	2501 Other
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Aut-xxi Investment Holdings Limited	2201 Interest of corporation controlled by you
Jnry V Holdings Limited	2101 Beneficial owner
Aut-xxi Hk Holdings Limited	2101 Beneficial owner
Aut-xxi Holdings Limited	2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Super Novel International Limited	2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines